Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CEST
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
05/27 REGENERON PHARMACEUTICALS : Announces ANGPTL3/Evinacumab Publication in New Engl..
05/25 REGENERON PHARMACEUTICALS : Report Summarizes Immunoglobulins Study Findings fro..
05/25 REGENERON PHARMACEUTICALS : Genetic Mutation Studies Help Validate New Strategy ..
05/25 SANOFI : FDA approves Sanofi and Regenerons Kevzara for adult rheumatoid arthrit..
05/24 REGENERON PHARMACEUTICALS : Announces ANGPTL3/Evinacumab Publication in New Engl..
05/24 SANOFI : Regeneron RA Drug Kevzara Wins FDA Approval
05/23 BIOTECH MOVERS : Puma Biotechnology Inc (NASDAQ:PBYI) and Regeneron Pharmaceutic..
05/23 SANOFI : and Regeneron Announce FDA Approval of Kevzara (Sarilumab) for the Trea..
05/22 REGENERON PHARMACEUTICALS : and Sanofi Announce FDA Approval of Kevzara® (sarilu..
05/19 REGENERON PHARMACEUTICALS : Pharma exec says industry must get fair about pricin..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/24 After Hours Gainers / Losers
05/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 24, 2017 - FDA Makes History
05/24 BBP : A Diversified Biotech ETF
05/23 Sanofi and Regeneron's RA med Kevzara faces crowded market
Advertisement
Financials ($)
Sales 2017 5 482 M
EBIT 2017 2 210 M
Net income 2017 1 019 M
Finance 2017 2 119 M
Yield 2017 -
P/E ratio 2017 51,75
P/E ratio 2018 40,31
EV / Sales 2017 8,44x
EV / Sales 2018 7,40x
Capitalization 48 380 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 441 $
Spread / Average Target -3,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..23.99%48 380
AMGEN, INC.6.02%113 994
CELGENE CORPORATION0.89%91 185
GILEAD SCIENCES, INC.-9.93%84 284
ACTELION LTD24.38%30 602
VERTEX PHARMACEUTICALS..62.78%29 868
More Results